Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation
Experimental & Molecular Medicine
;
: 311-318, 2012.
Article
in English
| WPRIM
| ID: wpr-153076
ABSTRACT
In this study, the synergistic effect of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone (cilostazol) and Ginkgo biloba extract (GbE) was examined in apolipoprotein E (ApoE) null mice. Co-treatment with GbE and cilostazol synergistically decreased reactive oxygen species (ROS) production in ApoE null mice fed a high-fat diet. Co-treatment resulted in a significantly decreased atherosclerotic lesion area compared to untreated ApoE mice. The inflammatory cytokines and adhesion molecules such as monocyte chemoattractant-1 (MCP-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and VCAM-1 which can initiate atherosclerosis were significantly reduced by the co-treatment of cilostazol with GbE. Further, the infiltration of macrophages into the intima was decreased by co-treatment. These results suggest that co-treatment of GbE with cilostazol has a more potent anti-atherosclerotic effect than treatment with cilostazol alone in hyperlipidemic ApoE null mice and could be a valuable therapeutic strategy for the treatment of atherosclerosis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Apolipoproteins E
/
Tetrazoles
/
Plant Extracts
/
Cytokines
/
Reactive Oxygen Species
/
Ginkgo biloba
/
Disease Models, Animal
/
Drug Synergism
/
Atherosclerosis
/
Macrophages
Limits:
Animals
/
Humans
/
Male
Language:
English
Journal:
Experimental & Molecular Medicine
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS